1 ibed hormone replacement therapy formulation Premarin.

2 ations and in new prescriptions for low-dose Premarin.

3 2003 declined by 66% for Prempro and 33% for Premarin.

4 ize of cholinergic neurons was unaffected by Premarin.

5 cipants were randomized into 3 groups: oCEE (Premarin, 0.45 mg/d), tE2 (Climara, 50 mug/d) both with

6   Equilin and equilenin, major components of Premarin, are predominantly metabolized to 4-hydroxyequi

7 nd treated with conjugated equine estrogens (Premarin) at doses that are equivalent to those currentl

8 ontrol), group 2 (n = 22) received estrogen (Premarin) at the human equivalent of 0.625 mg/day, and g

9 er, long-term exposure to estrogens from the Premarin drug increases the risk of breast cancer.

10 ogen (control, C) and 11 others on estrogen (Premarin, E) were studied basally and after 1 year.

11 -1 (hGST P1-1) by the catechol metabolite of Premarin estrogens, 4-hydroxyequilenin (4-OHEN), was (we

12 f androgen-independent prostate cancer, oral premarin has been shown to induce of prostate specific a

13   These findings suggest that treatment with Premarin has selective beneficial effects on cholinergic

14                                     The drug Premarin is the most widely used formula for hormone rep

15 he intermediate region (Ch4i) was greater in Premarin-treated monkeys as compared to controls and num

16 al band (MS/DB), no effect of treatment with Premarin was observed in the cholinergic neurons in eith

17 mine whether use of postmenopausal estrogen (Premarin, Wyeth-Ayerst, Philadelphia, PA) in women with